Albiglutide Beats Placebo for Cardiovascular Events in T2DM
THURSDAY, Oct. 4, 2018 -- For patients with type 2 diabetes and existing cardiovascular disease, albiglutide results in fewer cardiovascular events, according to a study published online Oct. 2 in The Lancet to coincide with the annual meeting of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Pharmaceuticals | Study